What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Nerandomilast demonstrated moderate benefit over current care, particularly in preserving lung function as evidenced by the phase 3 trials. The pivotal phase 3 trials showed treatment differences in FVC decline of 64 mL and 48 mL compared to placebo, indicating a significant but not overwhelmingly superior outcome. However, the evidence is primarily focused on lung function rather than broader clinical event benefits.
Does the economic case hold at the expected price? — Cost effectiveness
There is no public cost-utility analysis, ICER, or robust economic model available for nerandomilast. The absence of these critical economic evaluations means that the cost-effectiveness of the treatment cannot be determined, leading to a high uncertainty regarding its value proposition.
Is there quality-of-life evidence payers weigh? — Quality of life
While the program utilized validated HRQoL instruments, there is a lack of published numerical outputs or peer-reviewed data on QALY inputs. The absence of quantified improvements in patient-reported outcomes limits the ability to assess the treatment’s impact on quality of life, which is a significant concern for HTA bodies.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Nerandomilast has a credible safety profile with manageable adverse effects, primarily gastrointestinal issues like diarrhea. The reported rates of adverse events are consistent with existing therapies, and the overall safety data from phase 3 trials support its tolerability, although long-term risks remain uncertain.
Was the drug compared against what payers expect? — Comparator Selection
The use of placebo as a comparator in the phase 3 trials is acceptable for regulatory purposes but does not provide head-to-head evidence against established therapies like nintedanib or pirfenidone. This limits the ability to assess relative efficacy in a real-world context.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial populations for both IPF and PPF are broadly representative of the intended patient populations, with appropriate inclusion criteria. However, there are some limitations regarding the representation of more severe cases, which could affect generalizability.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Nerandomilast fits well into existing treatment pathways for IPF and PPF, serving as either an additional option or an add-on therapy. The integration appears straightforward, although optimal sequencing with existing therapies is not yet evidence-based.
Are the wider system costs understood? — Resource Use and Cost Implications
While the treatment is oral and may have operational advantages, there is a lack of public data quantifying the resource implications of its use. The absence of a budget impact model or resource-use study limits the ability to assess its economic feasibility.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base for nerandomilast is strong, supported by large randomized phase 3 trials and regulatory labeling. However, methodological weaknesses exist, particularly regarding the lack of active-comparator trials and incomplete HRQoL data.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are significant uncertainties regarding the long-term outcomes and economic value of nerandomilast, particularly in relation to HRQoL and cost-effectiveness. The absence of real-world evidence further complicates the assessment of its broader impacts.
